diacerein controlled release (AC 201) / TWi Biotechnology - LARVOL DELTA

A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy (clinicaltrials.gov) - P2; N=22; Completed; Sponsor: TWi Biotechnology, Inc.; Recruiting ➔ Completed

Clinical • Trial completion • Hemophilia • MRI

Divergent Response Profile in Activated Cord Blood T cells from First-born Child Implies Birth-order-associated in Utero Immune Programming. (PubMed) - "First-born infants display a reduced anti-inflammatory profile in T cells at birth. This possible in utero 'birth-order' T cell programing may contribute to later development of immune-mediated diseases by increasing overall immune reactivity in first-born children as compared to younger siblings."

Journal • Biosimilar

TWi Pharmaceuticals: Commercial Update (TWi Pharmaceuticals) - Anticipated patent expiry in Europe and Russia in 2030

Anticipated patent expiry • Immunology

TWi Biotechnology announces last patient enrolled in phase 2 study of AC-201CR for gout treatment (PRNewswire) - P2, N=127; NCT02287818; "TWi Biotechnology...announced today that it has completed patient enrollment in its Phase 2 clinical trial (Study code: AC-201-GOU-002) of AC-201CR for the treatment of gout. The Company expects to report top-line results from this study in the fourth quarter of 2016."

Anticipated P2 data • Enrollment closed • Immunology

TWi Pharmaceuticals announces positive phase IIb clinical trial results of AC-201 in patients with type 2 diabetes (PRNewswire) - P2, N=259; NCT01276106; AC-201 showed placebo-corrected reductions in HbA1c of 0.20%, 0.29%, and 0.35% after 24 weeks of treatment in the three tested dose groups of 25mg, 50mg, and 75mg twice daily, respectively; AC-201 showed good dose response and was well tolerated up to 75mg twice daily

P2 data • Diabetes